Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | HTR2C | P28335 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113597 | 0.90 | SYK (0.47) | SYKHTR2AHTR2CABL1GSK3A | |
| SCHEMBL17129790 | 0.87 | SYK (0.42) | SYKHTR2AHTR2CABL1BCR | |
| SCHEMBL17113604 | 0.83 | SYK (0.55) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17113328 | 0.80 | SYK (0.54) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17113385 | 0.78 | SYK (0.75) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17129840 | 0.77 | SYK (0.62) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17113602 | 0.75 | SYK (0.70) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17113444 | 0.75 | SYK (0.70) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL17113599 | 0.75 | SYK (0.54) | SYKJAK2JAK1TYK2JAK3 | |
| SCHEMBL18627915 | 0.72 | SYK (0.45) | SYKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, ZAP70, LCK | SYK 1/4885HTR2A 4092/4885HTR2C 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.